This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Real validated HAMP Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-HAMP WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
| Expected band | ~9.4 kDa | |
| Gel | 15% (standard starting point) | |
| Negative control | Suggested KO / knockdown lysate |
| PTM | Cleaved | |
| Caveat | Precursor versus mature forms | |
| Gene-set association | MSigDB C7 membership | |
| Isoform | 1 isoform(s) |
The M01347 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | Human Hepcidin Full-length Recombinant Protein (GFP Tagged) (catalog M01347) |
| Gel % | 15% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Short semi-dry transfer; verify retention (standard starting point) |
| Membrane | 0.2 µm PVDF (standard starting point) |
| Blocking | 5% milk or 5% BSA in TBST (standard starting point) |
| Primary antibody | M01347; use the WB datasheet starting dilution (standard starting point) |
| Primary incubation | Overnight at 4 °C (standard starting point) |
| Secondary antibody | Species-matched HRP conjugate at validated dilution (standard starting point) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL; bracket exposures to avoid saturation (standard starting point) |
Hepcidin’s full-length precursor is predicted at 9.4 kDa; secretion and cleavage may change what appears, but no migration pattern is demonstrated here.
| Band near 9.4 kDa | Compatible with the full-length precursor; confirm identity with controls. |
| Band below 9.4 kDa | Could reflect removal of the signal peptide at residues 1–24. |
| Smaller processed band | Could reflect removal of the propeptide at residues 25–54. |
| Little or no band in whole-cell lysate | Hepcidin is secreted. |
| Full-length precursor | Predicted mass is 9.4 kDa; migration has not been measured here. |
| Signal peptide at residues 1–24 | Its removal reduces the size of the precursor. |
| Propeptide at residues 25–54 | Its removal yields a smaller mature peptide. |
| Sequential signal-peptide and propeptide cleavage | The mature product is smaller than either the full-length precursor or the signal-cleaved intermediate. |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | Hepcidin is secreted. | Check conditioned medium alongside lysate. |
| Band lower than expected | Signal-peptide or propeptide cleavage may produce a smaller form. | Compare precursor and processed samples with an antibody known to recognize each form. |
| Band higher than expected | An intact precursor may appear above a processed form. | Compare with a full-length precursor control and verify band identity. |
| Multiple bands | Precursor and processed forms may coexist. | Compare lysate and conditioned medium and verify antibody recognition of each form. |
| Weak or no signal | The secreted protein may be scarce in the tested fraction. | Test conditioned medium and include a positive control. |
| Fragments below expected size | Propeptide processing yields a smaller product. | Verify the antibody epitope and compare with a processed-form control. |
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| No high/medium HPA tissues identified in the supplied evidence. | ||||
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| No lower-expression tissue rows available in the supplied evidence. | ||||
Deeper troubleshooting and optimisation questions for HAMP, answered from its protein features.
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
The catalog reports one anti-HAMP antibody, M01347, for Western blot. Its image shows human full-length recombinant hepcidin with a GFP tag. The supplied evidence does not show endogenous HAMP or a rat Western blot.
Which to pick: M01347 is the only listed option. Its reported reactivity is human and rat, but the supplied Western blot image uses GFP-tagged human recombinant protein; consider that sample difference when planning your blot.